Abstract
Background & Objective: 6-[(1S)-1-[1-[5-(2-hydroxyethoxy)-2-pyridyl]pyrazol-3-yl]ethyl]- 3H-1,3-benzothiazol-2-one (LY3130481 or CERC-611) is a selective antagonist of AMPA receptors containing transmembrane AMPA receptor regulatory protein (TARP) γ-8 that is under development for epilepsy. The present study provided a broad inquiry into its anticonvulsant properties. LY3130481 was anticonvulsant in multiple acute seizure provocation models in mice and rats. In addition, LY3130481 was effective against absence seizures in the GAERS genetic model and in the Frings mouse model. Likewise, LY3130481 attenuated convulsions in mice and rats with long-term induction of seizures (e.g., corneal, pentylenetetrazole, hippocampal, and amygdala kindled seizures). In slices of epileptic human cortex, LY3130481 significantly decreased neuronal firing frequencies. LY3130481 displaced from rat brain a radioligand specific for AMPA receptors associated with TARP γ-8 whereas non-TARP-selective molecules did not. Binding was also observed in hippocampus freshly transected from a patient.
Results & Conclusion: Taken as a whole, the findings reported here establish the broad anticonvulsant efficacy of LY3130481 indicating that blockade of AMPA receptors associated with TARP γ-8 is sufficient for these protective effects.
Keywords: AMPA receptors, antagonist, anticonvulsant activity, CERC-611, LY3130481, TARP-g8, transmembrane.
CNS & Neurological Disorders - Drug Targets
Title:Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611)
Volume: 16 Issue: 10
Author(s): Jeffrey M. Witkin*, Douglas A. Schober, Scott D. Gleason, John T. Catlow, Warren J. Porter, Jon Reel, Xiaoming Jin, Jonathan Hobbs, Donald Gehlert, Douglas L. Gernert, Kevin M. Gardinier, Akihiko S. Kato, Xingjie Ping and Jodi L. Smith
Affiliation:
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana,United States
Keywords: AMPA receptors, antagonist, anticonvulsant activity, CERC-611, LY3130481, TARP-g8, transmembrane.
Abstract: Background & Objective: 6-[(1S)-1-[1-[5-(2-hydroxyethoxy)-2-pyridyl]pyrazol-3-yl]ethyl]- 3H-1,3-benzothiazol-2-one (LY3130481 or CERC-611) is a selective antagonist of AMPA receptors containing transmembrane AMPA receptor regulatory protein (TARP) γ-8 that is under development for epilepsy. The present study provided a broad inquiry into its anticonvulsant properties. LY3130481 was anticonvulsant in multiple acute seizure provocation models in mice and rats. In addition, LY3130481 was effective against absence seizures in the GAERS genetic model and in the Frings mouse model. Likewise, LY3130481 attenuated convulsions in mice and rats with long-term induction of seizures (e.g., corneal, pentylenetetrazole, hippocampal, and amygdala kindled seizures). In slices of epileptic human cortex, LY3130481 significantly decreased neuronal firing frequencies. LY3130481 displaced from rat brain a radioligand specific for AMPA receptors associated with TARP γ-8 whereas non-TARP-selective molecules did not. Binding was also observed in hippocampus freshly transected from a patient.
Results & Conclusion: Taken as a whole, the findings reported here establish the broad anticonvulsant efficacy of LY3130481 indicating that blockade of AMPA receptors associated with TARP γ-8 is sufficient for these protective effects.
Export Options
About this article
Cite this article as:
Witkin M. Jeffrey *, Schober A. Douglas, Gleason D. Scott , Catlow T. John , Porter J. Warren , Reel Jon , Jin Xiaoming, Hobbs Jonathan, Gehlert Donald, Gernert L. Douglas , Gardinier M. Kevin , Kato S. Akihiko, Ping Xingjie and Smith L. Jodi, Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611), CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527316666171101132047
DOI https://dx.doi.org/10.2174/1871527316666171101132047 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry Syncope: Review of Monitoring Modalities
Current Cardiology Reviews Editorial:Cannabis: Neurological Correlates in Abuse and Medical Use
CNS & Neurological Disorders - Drug Targets Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management
Current Neuropharmacology Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Pharmacological Strategies for Neuroprotection in Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent
Current Alzheimer Research Aminoalkylpyridines (AAPs), Triazoline Metabolite Analogues, As Anticonvulsants Highly Effective in the Mes Test
Current Medicinal Chemistry Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer’s Disease
Current Alzheimer Research The Prophylactic Use of Antiepileptic Drugs in Patients Scheduled for Neurosurgery
Current Pharmaceutical Design Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology Novel Treatment Options of Binge Eating Disorder
Current Medicinal Chemistry Current Surgical Options for Patients with Epilepsy
Current Pharmaceutical Design Genome-wide Membrane Protein Structure Prediction
Current Genomics Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Current Neuropharmacology DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics